13F Holdings
中文EN

AVIR Atea Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1593899 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-5.7%
TTM EPS YoY-10.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-63.2%
ROA-57.2%
ROIC (approx.)-86.0%
Asset turnover—

Leverage & solvency

Liabilities / assets12.5%
Debt / equity0.00x
Current ratio8.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-5.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$27.09M$28.15M$41.13M$47.82M$38.35M$32.27M$29.58M$25.67M
SG&A expense$6.92M$6.95M$6.87M$7.12M$7.22M$9.07M$9.46M$13.36M
Operating income-$34.01M-$35.10M-$48.01M-$54.93M-$45.57M-$41.34M-$39.04M-$39.03M
Pretax income-$32.12M-$32.91M-$45.39M-$51.63M-$41.85M-$36.95M-$34.07M-$33.32M
Income tax$38,000$24,000$50,000-$6.77M$196,000$207,000$203,000$225,000
Net income-$32.16M-$32.93M-$45.44M-$44.87M-$42.05M-$37.16M-$34.27M-$33.54M
EBITDA-$33.91M-$34.99M-$47.90M-$54.83M-$45.46M-$41.24M-$38.94M-$38.92M
EPS (basic)-0.40-0.41-0.57—-0.53-0.44-0.40—
EPS (diluted)-0.40-0.41-0.57—-0.53-0.44-0.40—
Weighted avg. shares (diluted)80.22M80.05M79.20M—79.05M83.75M85.16M—
Balance sheet
Cash & equivalents$97.92M$76.55M$79.32M$95.71M$77.34M$87.72M$119.39M$64.70M
Short-term investments$93.28M$142.92M$176.69M$206.12M$251.97M$291.99M$306.04M$390.02M
Current assets$200.27M$228.66M$263.20M$310.99M$336.14M$385.60M$433.71M$462.36M
PP&E, net$145,000$249,000$353,000$457,000$561,000$665,000$769,000$873,000
Total assets$200.71M$232.28M$267.08M$315.22M$342.96M$391.61M$439.96M$464.67M
Current liabilities$25.02M$28.12M$33.37M$39.78M$20.18M$20.12M$21.75M$18.60M
Total liabilities$25.02M$28.12M$33.37M$39.78M$27.18M$27.19M$28.88M$25.80M
Shareholders' equity$175.68M$204.16M$233.71M$275.43M$315.78M$364.42M$411.08M$438.87M
Shares outstanding80.30M80.20M80.03M78.13M78.13M81.14M85.58M84.46M
Cash flow statement
Operating cash flow-$28.87M-$37.08M-$46.39M-$28.22M-$40.38M-$32.87M-$30.56M-$30.40M
Investing cash flow$50.05M$34.31M$29.74M$46.59M$41.30M$15.29M$85.61M-$3.37M
Financing cash flow$195,000$0$257,000$0-$11.30M-$14.09M-$347,000$0
Depreciation & amortization$104,000$104,000$104,000$104,000$104,000$104,000$104,000$104,000
Stock-based compensation$3.47M$3.38M$3.73M$4.58M$4.52M$4.67M$6.95M$14.30M
Share buybacks———$0$11.43M———

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.